Cassava Sciences (SAVA) Competitors $2.55 -0.11 (-4.14%) (As of 12/17/2024 05:56 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SAVA vs. ANAB, CRMD, XERS, RNAC, ABVX, MGTX, GLUE, ESPR, CDXC, and TKNOShould you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include AnaptysBio (ANAB), CorMedix (CRMD), Xeris Biopharma (XERS), Cartesian Therapeutics (RNAC), ABIVAX Société Anonyme (ABVX), MeiraGTx (MGTX), Monte Rosa Therapeutics (GLUE), Esperion Therapeutics (ESPR), ChromaDex (CDXC), and Alpha Teknova (TKNO). These companies are all part of the "pharmaceutical products" industry. Cassava Sciences vs. AnaptysBio CorMedix Xeris Biopharma Cartesian Therapeutics ABIVAX Société Anonyme MeiraGTx Monte Rosa Therapeutics Esperion Therapeutics ChromaDex Alpha Teknova AnaptysBio (NASDAQ:ANAB) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Does the MarketBeat Community favor ANAB or SAVA? AnaptysBio received 268 more outperform votes than Cassava Sciences when rated by MarketBeat users. Likewise, 66.06% of users gave AnaptysBio an outperform vote while only 65.33% of users gave Cassava Sciences an outperform vote. CompanyUnderperformOutperformAnaptysBioOutperform Votes36666.06% Underperform Votes18833.94% Cassava SciencesOutperform Votes9865.33% Underperform Votes5234.67% Do analysts rate ANAB or SAVA? AnaptysBio presently has a consensus target price of $45.09, suggesting a potential upside of 181.99%. Cassava Sciences has a consensus target price of $111.50, suggesting a potential upside of 4,272.55%. Given Cassava Sciences' higher probable upside, analysts clearly believe Cassava Sciences is more favorable than AnaptysBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AnaptysBio 0 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.67Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals & insiders hold more shares of ANAB or SAVA? 38.0% of Cassava Sciences shares are owned by institutional investors. 33.7% of AnaptysBio shares are owned by insiders. Comparatively, 12.2% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to ANAB or SAVA? In the previous week, AnaptysBio had 17 more articles in the media than Cassava Sciences. MarketBeat recorded 39 mentions for AnaptysBio and 22 mentions for Cassava Sciences. AnaptysBio's average media sentiment score of 0.20 beat Cassava Sciences' score of 0.13 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 6 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Neutral Cassava Sciences 4 Very Positive mention(s) 1 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ANAB or SAVA more profitable? Cassava Sciences has a net margin of 0.00% compared to AnaptysBio's net margin of -289.75%. Cassava Sciences' return on equity of -88.05% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets AnaptysBio-289.75% -287.94% -37.25% Cassava Sciences N/A -88.05%-64.98% Which has more volatility & risk, ANAB or SAVA? AnaptysBio has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -0.86, suggesting that its share price is 186% less volatile than the S&P 500. Which has better earnings & valuation, ANAB or SAVA? Cassava Sciences has lower revenue, but higher earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnaptysBio$57.17M8.51-$163.62M-$6.08-2.63Cassava SciencesN/AN/A-$97.22M-$1.38-1.85 SummaryAnaptysBio beats Cassava Sciences on 10 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaAI Crypto Tool Could Send One Coin SOARING…The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectDiscover our #1 crypto pick before it's too late. Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAVA vs. The Competition Export to ExcelMetricCassava SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$125.09M$6.50B$4.98B$9.29BDividend YieldN/A3.06%4.79%4.06%P/E Ratio-1.8810.57134.7017.50Price / SalesN/A284.751,266.50142.95Price / CashN/A56.6540.1437.96Price / Book0.805.444.894.90Net Income-$97.22M$150.81M$117.51M$225.09M7 Day Performance-10.03%-5.42%14.47%-1.43%1 Month Performance-90.34%0.40%17.44%5.36%1 Year Performance-87.67%16.08%36.36%22.53% Cassava Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAVACassava Sciences4.5587 of 5 stars$2.55-4.1%$111.50+4,272.5%-87.9%$122.68MN/A-1.8530ANABAnaptysBio2.3992 of 5 stars$17.05+9.4%$45.09+164.5%-16.9%$518.83M$17.16M-2.80100Short Interest ↑Analyst RevisionCRMDCorMedix2.3198 of 5 stars$8.52+1.7%$15.20+78.4%+158.0%$516.97M$12.26M-10.3530Positive NewsXERSXeris Biopharma3.907 of 5 stars$3.43+4.6%$4.87+41.9%+68.8%$511.34M$163.91M-7.29290Positive NewsRNACCartesian Therapeutics2.644 of 5 stars$19.90+6.5%$43.00+116.1%-18.4%$505.86M$26M-0.3537Positive NewsABVXABIVAX Société Anonyme2.2762 of 5 stars$7.94+11.7%$38.67+387.0%-24.4%$502.98MN/A0.0061Positive NewsGap DownMGTXMeiraGTx4.2578 of 5 stars$6.37+4.1%$23.50+268.9%+42.2%$497.84M$13.93M-5.06300GLUEMonte Rosa Therapeutics2.4508 of 5 stars$7.77+2.8%$16.00+105.9%+53.4%$477.37M$14.98M-4.1390ESPREsperion Therapeutics3.9825 of 5 stars$2.42+7.6%$8.17+237.5%+35.2%$476.83M$295.45M-3.69240Analyst ForecastGap UpCDXCChromaDex4.6785 of 5 stars$6.11-0.2%$8.00+30.9%+334.8%$466.70M$91.67M620.00106Analyst DowngradeTKNOAlpha Teknova0.8898 of 5 stars$8.73+8.7%$5.00-42.7%+131.5%$465.40M$36.68M-11.73240Gap Up Related Companies and Tools Related Companies AnaptysBio Competitors CorMedix Competitors Xeris Biopharma Competitors Cartesian Therapeutics Competitors ABIVAX Société Anonyme Competitors MeiraGTx Competitors Monte Rosa Therapeutics Competitors Esperion Therapeutics Competitors ChromaDex Competitors Alpha Teknova Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SAVA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
